Core Viewpoint - A securities class action lawsuit has been filed against Lockheed Martin Corporation, alleging that the company misled investors regarding its financial health and internal controls from January 23, 2024, to July 21, 2025 [1][2]. Group 1: Allegations and Misrepresentations - The lawsuit claims Lockheed Martin overstated its operational capabilities, particularly in the Aeronautics and Rotary and Mission Systems (RMS) segments, and lacked effective internal controls to assess program risks [2]. - Investors were not informed of the potential for significant losses due to these inadequate internal controls, which the lawsuit suggests were systemic issues rather than isolated incidents [5]. Group 2: Financial Disclosures and Impact - A series of negative disclosures led to substantial stock price drops, with shares falling nearly 11% following the final disclosure [3]. - Specific financial losses reported include $1.8 billion in pre-tax losses in the Aeronautics segment on January 28, 2025, and an additional $950 million and $570 million in pre-tax losses for the Aeronautics and RMS segments, respectively, disclosed on July 22, 2025 [6]. Group 3: Legal and Investigative Actions - Hagens Berman is investigating the claims on behalf of investors who suffered losses, focusing on whether the company's management was aware of the inadequacies in internal controls and the risks involved [4][5]. - The firm encourages investors with substantial losses to come forward and assist in the investigation [2].

Core Viewpoint - A securities class-action lawsuit has been filed against Centene Corporation, alleging that the company misrepresented its financial health and market conditions to investors [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, targets investors who purchased Centene securities between December 12, 2024, and June 30, 2025 [1]. - The complaint claims that Centene's leadership provided a misleadingly optimistic view of projected revenue growth, strong enrollment, and low morbidity levels, which contradicted internal data [2]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 financial guidance after an independent actuarial review indicated that market growth was "lower than expected" and morbidity levels were "materially inconsistent" with prior assumptions, leading to a stock price drop of over 40% [3]. - Following the lawsuit, Centene reported a Q2 diluted loss per share of -$0.51, attributed to reduced revenue estimates [4]. Group 3: Investigation and Whistleblower Information - Hagens Berman, a national plaintiffs' rights law firm, is investigating claims on behalf of investors who suffered losses, focusing on whether Centene misrepresented its marketplace business health [5]. - The firm encourages whistleblowers with non-public information about Centene to come forward, offering potential rewards of up to 30% of any successful SEC recovery [5].